EUVIMEDEUVIMED entdecken
EditorialKommentar

Editorial Comment to Efficacy and safety of pembrolizumab and axitinib as first‐line treatment for patients with advanced renal cell carcinoma: Real‐world experience in Japan

Tsunenori Kondo

International Journal of Urology · 2023

DOI: 10.1111/iju.15256 ↗

Kurz gefasst

Editorial in der Zeitschrift International Journal of Urology, 2023. Verfasst von Tsunenori Kondo. Beteiligte Einrichtung: Department of Urology, Tokyo Women's Medical University Adachi Medical Center, Tokyo, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit nennt 5 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tsunenori Kondo received honoraria from Pfizer, MSD, Takeda Pharmaceuticals, and Ono Pharmaceutical.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsHumansAxitinibJapanAntibodies, Monoclonal, Humanized

Substanzen

AxitinibpembrolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Urology, Tokyo Women's Medical University Adachi Medical Center, Tokyo, Japan.

Zitieren

APA

Kondo, T. (2023). Editorial Comment to Efficacy and safety of pembrolizumab and axitinib as first‐line treatment for patients with advanced renal cell carcinoma: Real‐world experience in Japan. International Journal of Urology. https://doi.org/10.1111/iju.15256

Vancouver

Kondo T. Editorial Comment to Efficacy and safety of pembrolizumab and axitinib as first‐line treatment for patients with advanced renal cell carcinoma: Real‐world experience in Japan. International Journal of Urology. 2023. doi:10.1111/iju.15256

BibTeX
@article{Kondo2023,
  author = {Kondo, Tsunenori},
  title = {Editorial Comment to Efficacy and safety of pembrolizumab and axitinib as first‐line treatment for patients with advanced renal cell carcinoma: Real‐world experience in Japan},
  journal = {International Journal of Urology},
  year = {2023},
  doi = {10.1111/iju.15256}
}
Kostenlos starten →